Aug 19, 2020 | News, Regulatory
Gilead submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotnib, a treatment for rheumatoid arthritis, which the FDA rejected due to safety concerns, particular in the 200mg dose. “We are disappointed in this outcome and will... 
May 11, 2020 | News, Regulatory
The FDA announced on Friday (5/8) of its approval for Retevmo, a drug capsule created by Eli Lilly for patients diagnosed with a specific RET gene mutation for three kinds of tumors: non-small cell lung cancer, medullary thyroid cancer and other types of thyroid... 
Apr 20, 2020 | News, Regulatory
As part of an ongoing global study, MemorialCare Long Beach Center has administered the antiviral drug Remdesivir to three patients as a possible treatment for COVID-19. This news comes closely after Gilead, a biotech company based out of the California... 
Jan 23, 2020 | News, Regulatory
On November 14, 2019, the U.S. Food and Drug Administration gave approval to BeiGene Ltd’s lymphoma treatment. BeiGene is a Chinese biopharmaceutical company that focused on cancer treatments. The treatment “Brukinsa” has been tested on 118 patients... 
Jan 22, 2020 | News, Regulatory
What is NRDL? NRDL is introduced in 2000 to support medical healthcare and providing patients with basic medical treatments. Between 2000 and 2017, the NRDL has been updated twice, but the reimbursement process is poor. The third update is in 2018, where 10 new drugs...
